Noxopharm Ltd. (AU:NOX)
ASX:NOX
Want to see AU:NOX full AI Analyst Report?
Top Page
Noxopharm Ltd.
(Sydney:NOX)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.06
▼(-34.44% Downside)
Action:Reiterated
Date:04/17/26
The score is primarily held down by weak financial performance—large ongoing losses, continued cash burn, and a materially weaker 2025 balance sheet with higher leverage. Technicals provide partial support via positive trend and MACD, but the very high RSI signals stretched momentum. Valuation remains challenged due to negative earnings and no provided dividend yield.
Positive Factors
Focused oncology R&D
A clear, focused R&D mandate in oncology concentrates resources on a high-value therapeutic area. Persistent focus on anti-cancer drug development builds institutional expertise, preserves strategic clarity for partnerships or licensing, and sustains long-term value creation if clinical progress continues.
Negative Factors
Persistent losses and negative margins
Consistent negative gross profit and large operating losses indicate the core activities are not economically self-sustaining. Over a multi-month horizon this reduces internal funding capacity, limits reinvestment into R&D without external capital, and undermines margin recovery prospects absent material commercial breakthroughs.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology R&D
A clear, focused R&D mandate in oncology concentrates resources on a high-value therapeutic area. Persistent focus on anti-cancer drug development builds institutional expertise, preserves strategic clarity for partnerships or licensing, and sustains long-term value creation if clinical progress continues.
Read all positive factors
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.66M
Dividend YieldN/A
Average Volume (3M)123.50K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth-137.97%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Noxopharm Ltd. Business Overview & Revenue Model
Company Description
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherap...
How the Company Makes Money
null...
Noxopharm Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | |||||
| Total Assets | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | |||||
| Free Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Negative
0.09
Price Trends
0.07
Negative
0.07
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
37.28
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOX, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.28 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOX.
Noxopharm Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$27.76M | -25.86 | 10.35% | 2.81% | -18.17% | -70.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$68.35M | -5.28 | -62.49% | ― | ― | -13.64% | |
46 Neutral | AU$19.66M | -3.69 | 2509.60% | ― | ― | -137.97% | |
45 Neutral | AU$6.91M | -0.15 | 2844.96% | ― | ― | 62.07% | |
44 Neutral | AU$89.45M | -14.80 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$141.70M | -2.84 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:NOX
Noxopharm Ltd.
0.06
>-0.01
-3.03%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
35.42%
AU:CHM
Chimeric Therapeutics Ltd.
0.13
-0.04
-23.53%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.59
-1.01
-63.15%
AU:RCE
Recce Pharmaceuticals Ltd.
0.49
0.20
68.97%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-3.90%
Noxopharm Ltd. Corporate Events
Noxopharm Plans CEO Option Grant Tied to Long-Term Share Price Growth
May 8, 2026
Noxopharm Ltd. has notified the ASX of a proposed issue of up to 2 million new options to its chief executive officer, with an exercise price set at a 25% premium and an expiry date of 15 April 2030. The options, forming a new class of securities,...
Noxopharm Taps Novotech to Advance SOF-SKN Toward Key FDA Milestone
May 5, 2026
Noxopharm has engaged global clinical research organisation Novotech to support preparations for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its SOF-SKN candidate, part of the Sofra technology platform. Th...
Noxopharm Data Backs SOF-16’s Anti-Inflammatory Potential in Autoimmune Disease
Apr 30, 2026
Noxopharm has reported new data demonstrating the potential of its Sofra platform, showing that SOF-16, the active ingredient in its SOF-SKN cutaneous lupus candidate, exhibits strong anti-inflammatory effects in vitro on samples from patients wit...
Noxopharm Names CFO Shawn van Boheemen as New Company Secretary
Apr 29, 2026
Noxopharm Limited has appointed Chief Financial Officer Shawn van Boheemen as Company Secretary, effective immediately, following the resignation of long-serving secretary David Franks. The company highlighted van Boheemen’s three decades of...
Noxopharm deepens Sofra push with Tezcat deal, CEO shift and key trial progress
Apr 23, 2026
Noxopharm has strengthened its positioning in immunology drug development by signing a memorandum of understanding with U.S.-based Tezcat Biosciences to explore combining Sofra RNA assets with Tezcat’s targeted drug delivery system, aiming t...
Noxopharm’s SOF-SKN shows prolonged skin retention in preclinical study
Apr 21, 2026
Noxopharm Limited has reported new preclinical pharmacokinetic data for its cutaneous lupus candidate SOF-SKN, showing that the active ingredient SOF-16 has a skin half-life of about 3.5 days in both normal and disease-like tissue. The long reside...
Noxopharm Tightens Disclosure Controls After CEO Resigns and Director Notices Updated
Apr 14, 2026
Noxopharm has detailed changes in director interests following the resignation of Managing Director and CEO Dr Gisela Mautner on 14 April 2026, including the lodgement of a Final Director’s Interest Notice and a delayed Change of Director...
Noxopharm CEO Resigns as Biotech Awaits Successor Amid Strategic Shift
Apr 14, 2026
Noxopharm Limited, a clinical-stage Australian biotech specialising in cancer and inflammation therapies and mRNA safety-enhancing technologies, develops proprietary drugs through its Sofra and Chroma platforms in collaboration with specialist in-...
Noxopharm Half-Year Loss Widens as Net Tangible Assets Turn Negative
Feb 27, 2026
Noxopharm Limited reported a sharp widening of its half-year loss to $1.84 million for the period ended 31 December 2025, a 49% increase from the prior corresponding period’s $1.24 million loss. The company’s net tangible assets per sh...
Noxopharm Issues 15 Million New Shares Under Financing Facility
Feb 27, 2026
Noxopharm Limited has issued 15 million fully paid ordinary shares at an issue price of zero dollars per share under a financing facility announced on 27 February 2026, expanding its capital base without providing a disclosure document to investor...
Noxopharm Issues 15 Million New Shares Under Financing Facility
Feb 27, 2026
Noxopharm Ltd has applied for quotation on the ASX of 15 million new ordinary fully paid shares issued on 27 February 2026. The shares were created in connection with a new financing facility, with the share issue and execution of the related faci...
Noxopharm Secures $2.8m R&D Rebate to Advance Sofra Clinical Programs
Feb 27, 2026
Noxopharm has received a $2.8 million rebate under the Australian Government’s RD Tax Incentive scheme for FY2025, bolstering its cash reserves as it advances its Sofra technology platform and HERACLES clinical program. The funding supports ...
Noxopharm Secures Flexible $5m At-the-Market Equity Facility with Acuity Capital
Feb 27, 2026
Noxopharm Limited has entered into an At-the-Market Subscription Agreement with Acuity Capital, securing access to up to $5 million in standby equity capital over a five-year period to July 2031. The facility gives the company full discretion over...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.